A dengue virus type 4 model of disseminated lethal infection in AG129 mice

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Milligan, Gregg N ^a   Sarathy, Vanessa V ^a   Infante, Ernesto ^a   Li, Li ^a   Campbell, Gerald A ^a   Beatty, P Robert ^b   Harris, Eva ^b   Barrett, Alan D T ^a   Bourne, Nigel ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; CHEMOKINE; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; BLOOD CELL COUNT; BODY WEIGHT; CHEMOKINESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 4; FLAVIVIRUS; GENE SEQUENCE; HISTOPATHOLOGY; INNATE IMMUNITY; MORBIDITY; MOUSE; NONHUMAN; SEROLOGY; SEROTYPE; SURVIVAL RATE; VIREMIA; VIRUS STRAIN; VIRUS TITRATION; WEIGHT REDUCTION; ANIMAL; BLOOD; CELL COUNT; CHLOROCEBUS AETHIOPS; COMPLICATION; DENGUE VIRUS; DISEASE MODEL; HUMAN; IMMUNOLOGY; INTESTINE; LEUKOPENIA; LIVER; PATHOLOGY; PHYSIOLOGY; THROMBOCYTOPENIA; VASCULARIZATION; VERO CELL LINE; VIROLOGY;

ANIMALIA; DENGUE VIRUS TYPE 4; MUS;

ANIMALS; ANTIBODIES, VIRAL; CELL COUNT; CERCOPITHECUS AETHIOPS; CHEMOKINES; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; HUMANS; INTESTINES; LEUKOPENIA; LIVER; MICE; THROMBOCYTOPENIA; VERO CELLS; VIREMIA;

EID: 84929096181     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125476     Document Type: Article

References (30)

1. WHO. Dengue: guidelines for diagnosis, treatment, prevention, and control. New ed. Geneva: TDR: World Health Organization; 2009. 147 p. p.
2. Simmons CP, Farrar JJ, Nguyen v V, Wills B. Dengue. The New England journal of medicine. 2012; 366(15):1423-32. doi: 10.1056/NEJMra1110265 PubMed PMID: 22494122.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013; 496(7446):504-7. doi: 10.1038/nature12060 PubMed PMID: 23563266; PubMed Central PMCID: PMC3651993.
4. Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA, et al. Global spread of dengue virus types: mapping the 70 year history. Trends in microbiology. 2014; 22(3):138-46. doi: 10.1016/j.tim.2013.12.011 PubMed PMID: 24468533; PubMed Central PMCID: PMC3946041.
5. WHO. Dengue and Severe Dengue. 2014.
6. Cassetti MC, Halstead SB. Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland. Vaccine. 2014; 32(26):3115-21. doi: 10.1016/j.vaccine.2014.04.017 PubMed PMID: 24768502.
7. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of virology. 2013; 158(7):1445-59. doi: 10.1007/s00705-013-1645-3 PubMed PMID: 23471635.
8. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature reviews Immunology. 2011; 11(8):532-43. doi: 10.1038/nri3014 PubMed PMID: 21760609.
9. Clark KB, Onlamoon N, Hsiao HM, Perng GC, Villinger F. Can non-human primates serve as models for investigating dengue disease pathogenesis? Frontiers in microbiology. 2013; 4:305. doi: 10.3389/fmicb.2013.00305 PubMed PMID: 24130557; PubMed Central PMCID: PMC3795305.
10. Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis. Virology. 2014; 452-453:237-46. doi: 10.1016/j.virol.2014.01.015 PubMed PMID: 24606701.
11. Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, et al. Report of an NIAID workshop on dengue animal models. Vaccine. 2010; 28(26):4229-34. doi: 10.1016/j.vaccine.2010.04.045 PubMed PMID: 20434551; PubMed Central PMCID: PMC2919823.
12. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA, et al. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood. 2010; 115(9):1823-34. doi: 10.1182/blood-2009-09-242990 PubMed PMID: 20042723; PubMed Central PMCID: PMC2832810.
13. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. Journal of virology. 1999; 73(1):783-6. PubMed PMID: 9847388; PubMed Central PMCID: PMC103889.
14. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. Journal of virology. 2006; 80(20):10208-17. doi: 10.1128/JVI.00062-06 PubMed PMID: 17005698; PubMed Central PMCID: PMC1617308.
15. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell host & microbe. 2010; 7(2):128-39. doi: 10.1016/j.chom.2010.01.004 PubMed PMID: 20153282; PubMed Central PMCID: PMC2824513.
16. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, et al. An adenosine nucleoside inhibitor of dengue virus. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(48):20435-9. doi: 10.1073/pnas.0907010106 PubMed PMID: 19918064; PubMed Central PMCID: PMC2787148.
17. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS pathogens. 2010; 6(2):e1000790. doi: 10.1371/journal.ppat.1000790 PubMed PMID: 20168989; PubMed Central PMCID: PMC2820409.
18. Chang J, Schul W, Yip A, Xu X, Guo JT, Block TM. Competitive inhibitor of cellular alpha-glucosidases protects mice from lethal dengue virus infection. Antiviral research. 2011; 92(2):369-71. doi: 10.1016/j.antiviral.2011.08.003 PubMed PMID: 21854808; PubMed Central PMCID: PMC3209657.
19. Watanabe S, Rathore AP, Sung C, Lu F, Khoo YM, Connolly J, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral research. 2012; 96(1):32-5. doi: 10.1016/j.antiviral.2012.07.008 PubMed PMID: 22867971.
20. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS pathogens. 2013; 9(10): e1003723. doi: 10.1371/journal.ppat.1003723 PubMed PMID: 24204271; PubMed Central PMCID: PMC3814346.
21. Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS neglected tropical diseases. 2010; 4(4): e672. doi: 10.1371/journal.pntd.0000672 PubMed PMID: 20436920; PubMed Central PMCID: PMC2860513.
22. Tan GK, Ng JK, Lim AH, Yeo KP, Angeli V, Alonso S. Subcutaneous infection with non-mouse adapted Dengue virus D2Y98P strain induces systemic vascular leakage in AG129 mice. Annals of the Academy of Medicine, Singapore. 2011; 40(12):523-32. PubMed PMID: 22294063.
23. Sarathy VV, White M, Li L, Gorder SR, Pyles RB, Campbell GA, et al. A Lethal Murine Infection Model for Dengue Virus 3 in AG129 Mice Deficient in Type I and II Interferon Receptors Leads to Systemic Disease. Journal of virology. 2015; 89(2):1254-66. doi: 10.1128/JVI.01320-14 PubMed PMID: 25392217; PubMed Central PMCID: PMC4300670.
24. Wang E, Ni H, Xu R, Barrett AD, Watowich SJ, Gubler DJ, et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. Journal of virology. 2000; 74(7):3227-34. PubMed PMID: 10708439; PubMed Central PMCID: PMC111823.
25. Orozco S, Schmid MA, Parameswaran P, Lachica R, Henn MR, Beatty R, et al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. The Journal of general virology. 2012; 93(Pt 10):2152-7. doi: 10.1099/vir.0.045088-0 PubMed PMID: 22815273; PubMed Central PMCID: PMC3541791.
26. Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, et al. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. Journal of virology. 2013; 87(16):8826-42. doi: 10.1128/JVI.01314-13 PubMed PMID: 23785205; PubMed Central PMCID: PMC3754038.
27. Schoggins JW, Dorner M, Feulner M, Imanaka N, Murphy MY, Ploss A, et al. Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(36):14610-5. doi: 10.1073/pnas.1212379109 PubMed PMID: 22908290; PubMed Central PMCID: PMC3437900.
28. Carod-Artal FJ, Wichmann O, Farrar J, Gascon J. Neurological complications of dengue virus infection. Lancet neurology. 2013; 12(9):906-19. doi: 10.1016/S1474-4422(13)70150-9 PubMed PMID: 23948177.
29. Grant D, Tan GK, Qing M, Ng JK, Yip A, Zou G, et al. A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis. Journal of virology. 2011; 85(15):7775-87. doi: 10.1128/JVI.00665-11 PubMed PMID: 21632767; PubMed Central PMCID: PMC3147917.
30. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine. 2011; 29(42):7221-8. doi: 10.1016/j.vaccine.2011.07.022 PubMed PMID: 21781999.